Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
COMPLETED
NCT03381547
PHASE1
A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)
Sponsor: Eli Lilly and Company
View on ClinicalTrials.gov
Summary
To evaluate the pharmacokinetics of different dose levels and dose formulations of pegilodecakin in healthy adult participants.
Official title: An Open Label, Randomized, Single Dose, 3-Way Crossover Study to Evaluate the Pharmacokinetics of Different Dose Levels and Dose Formulations of AM0010 in Healthy Adult Subjects
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2017-12-18
Completion Date
2018-02-13
Last Updated
2026-07-07
Healthy Volunteers
Yes
Conditions
Interventions
BIOLOGICAL
Pegilodecakin
Pegilodecakin alone administered SQ
Locations (1)
PPD Development
Austin, Texas, United States